Shares in Cyclopharm Ltd (ASX: CYC) are down almost 50% over the past 12 months, but according to the analysts at Bell Potter, now could be a great time to buy in.
Bell Potter has a buy recommendation on the shares and a bullish price target, which I’ll get to shortly.
First, let’s have a look at the company’s recently released first-half results.
US market primed for growth
Cyclopharm’s flagship product is Technegas, which is a broad-spectrum diagnostic lung imaging technology for the visualisation of pulmonary ventilation and lung function.
The company said Technegas was now available in 67 countries, with more than five million patient procedures to date.
In the first half of 2026, Cyclopharm generated revenue of $17.5 million, up 14% on the same period last year, while revenue growth in the US jumped 74% to $2.1 million.
The company had $12.2 million in cash at the end of June, and posted a net loss of $8.8 million, compared with $7.7 million for the same period last year.
The company explained:
The movement reflects three factors: continued investment in US commercial operations; a near-doubling of research and development expenditure to $0.57 million as we advance our Beyond PE clinical programs; and the absence of the $1.1 million share of joint venture profit recorded in the pcp following the divestment of the non-core Cyclotek interest. Encouragingly, gross margin improved from 53.5% to 56.3%, reflecting the growing weighting of higher-margin Technegas revenue, and particularly US revenue, in the sales mix.
In terms of the market opportunity, Cyclopharm estimates the US market could be worth US$180 million.
Managing Director James McBrayer said:
The US is the world’s largest healthcare market and represents a potential US$180 million annual revenue opportunity for Cyclopharm in the diagnosis and management of Pulmonary Embolism alone. That potential is not speculative; it is built on the same adoption curve that has played out in each of our established markets, where Technegas commands an 85% or greater share of nuclear medicine ventilation imaging. Applying that experience, the Company sees its primary US market as approximately 2,000-site addressable market out of the 5,139 US sites performing nuclear medicine lung imaging, per CMS data. With 70 sites generating revenue as at 30 June 2026, we have only just started.
ASX biotech shares looking cheap
Bell Potter said in its note to clients that the growth was encouraging and noted that half of the top 20 hospitals in the US had now adopted Technegas.
The broker has a $1 price target on Cyclopharm shares compared to 50.5 cents currently.
The company is valued at $63.5 million.
The post Bell Potter says this ASX biotech could nearly double in value appeared first on The Motley Fool Australia.
Should you invest $1,000 in Cyclopharm right now?
Before you buy Cyclopharm shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cyclopharm wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why is everyone talking about Coles, Ramelius Resources and Woodside shares on Tuesday?
- Buy, hold, sell: DigiCo Infrastructure REIT, CBA, Telstra shares
- 3 amazing ASX ETFs for Aussie investors in September
- How many Coles shares do I need to buy for $5,000 a year in passive income?
- How much do I need in my superannuation to retire comfortably at age 60?
Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.